Recursion Pharmaceuticals missed its Q3 earnings estimates by 13.16% and reported a decrease in revenue compared to the same period last year. This is likely to negatively impact the company's stock price in the short term, especially considering that a similar miss in the previous quarter led to a 5.02% drop in the share price the next day.